Cancer

© American Cancer Society

Cover image for Vol. 123 Issue 15

Edited By: Fadlo R. Khuri, MD

Impact Factor: 5.997

ISI Journal Citation Reports © Ranking: 2016: 35/217 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

Highlighted Papers

  • The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer

    The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer

    Early adoption patterns of intensity-modulated radiotherapy and sterotactic body radiation treatment.

  • Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study

    Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study

    Imaging results from the neurofeedback group (top) and controls (bottom) in an intervention for chemotherapy-induced peripheral neuropathy.

  • Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis

    Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis

    A decision tree for breast cancer prevention strategies in lobular carcinoma in situ.

  • A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors

    A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors

    Distribution of BMI changes among breast cancer survivors.

  • Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer

    Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer

    A breast tumor reclassified from equivocal to amplified using the alternative chromosome 17 probe D17S122.

  • A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma

    A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma

    Total MET immunohistochemistry in patients with advanced cholangiocarcinoma.

  • The American Cancer Society's Cancer Prevention Study 3 (CPS-3): Recruitment, study design, and baseline characteristics

    The American Cancer Society's Cancer Prevention Study 3 (CPS-3): Recruitment, study design, and baseline characteristics

    Cancer Prevention Study 3 enrollment states and locations of regional processing laboratories are illustrated.

  • Treatment-associated toxicities reported by patients with early-stage invasive breast cancer

    Treatment-associated toxicities reported by patients with early-stage invasive breast cancer

    Distribution of health care service use by symptom severity.

  • The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer
  • Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study
  • Breast cancer prevention strategies in lobular carcinoma in situ: A decision analysis
  • A prospective evaluation of clinical and genetic predictors of weight changes in breast cancer survivors
  • Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer
  • A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma
  • The American Cancer Society's Cancer Prevention Study 3 (CPS-3): Recruitment, study design, and baseline characteristics
  • Treatment-associated toxicities reported by patients with early-stage invasive breast cancer

Recently Published Issues

See all

Cancer Highlights

Cancer Articles

ACA Editorial



Dr. Kantarjian reflects on 3 years of the Affordable Care Act: successes, problems and solutions. Read the full article here.


Cancer Editor Highlights



Increased Impact factor for 2016 is 5.997!

Regulations and policies regarding e-cigarettes

Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks

Overall survival with ponatinib versus allogenic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T3151 mutation

Insurance denials for cancer clinical trial participation after the Affordable Care Act mandate

CancerScope

Cancer diagnosis

CancerScope

CancerScope

First Person: Rainer Storb, MD

The pioneer in bone marrow transplantation continues to push the innovation envelope while inspiring a new generation of researchers.

Click here to read this article
Click here to download the PDF




Stay up-to-date with
Cancer
Like Cancer on FacebookFollow Cancer on TwitterFollow Cancer on Google Follow Cancer on Figure 1

SEARCH

SEARCH BY CITATION